US20130178412A1 - Dihydroxyproply-cysteine peptide and agent containing this peptide - Google Patents
Dihydroxyproply-cysteine peptide and agent containing this peptide Download PDFInfo
- Publication number
- US20130178412A1 US20130178412A1 US12/211,561 US21156108A US2013178412A1 US 20130178412 A1 US20130178412 A1 US 20130178412A1 US 21156108 A US21156108 A US 21156108A US 2013178412 A1 US2013178412 A1 US 2013178412A1
- Authority
- US
- United States
- Prior art keywords
- composition according
- peptide
- dihydroxypropyl
- cysteine
- acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 11
- GPWYBXDQHZIBPR-AKGZTFGVSA-N (2r)-2-amino-3-(2,3-dihydroxypropylsulfanyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CSCC(O)CO GPWYBXDQHZIBPR-AKGZTFGVSA-N 0.000 claims abstract description 8
- 150000002148 esters Chemical class 0.000 claims abstract description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 150000001413 amino acids Chemical group 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000002924 anti-infective effect Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000012050 conventional carrier Substances 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims description 2
- 230000036303 septic shock Effects 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 239000012646 vaccine adjuvant Substances 0.000 claims description 2
- 229940124931 vaccine adjuvant Drugs 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 150000007513 acids Chemical class 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 244000144972 livestock Species 0.000 claims 1
- -1 dihydroxypropyl group Chemical group 0.000 abstract description 5
- 150000004668 long chain fatty acids Chemical group 0.000 abstract description 3
- 108010028921 Lipopeptides Proteins 0.000 description 6
- 102000004895 Lipoproteins Human genes 0.000 description 5
- 108090001030 Lipoproteins Proteins 0.000 description 5
- 241000204031 Mycoplasma Species 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- GPWYBXDQHZIBPR-UHNVWZDZSA-N (2r)-2-amino-3-[(2r)-2,3-dihydroxypropyl]sulfanylpropanoic acid Chemical compound OC(=O)[C@@H](N)CSC[C@H](O)CO GPWYBXDQHZIBPR-UHNVWZDZSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- SEKBHZJLARBNPB-GHCJXIJMSA-N Asn-Ile-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O SEKBHZJLARBNPB-GHCJXIJMSA-N 0.000 description 1
- DGKCOYGQLNWNCJ-ACZMJKKPSA-N Asp-Glu-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O DGKCOYGQLNWNCJ-ACZMJKKPSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- BBBXWRGITSUJPB-YUMQZZPRSA-N Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O BBBXWRGITSUJPB-YUMQZZPRSA-N 0.000 description 1
- CIMULJZTTOBOPN-WHFBIAKZSA-N Gly-Asn-Asn Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CIMULJZTTOBOPN-WHFBIAKZSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000202952 Mycoplasma fermentans Species 0.000 description 1
- 241000204003 Mycoplasmatales Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000015961 delipidation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the macrophage-stimulating activity of mycoplasma has been known for a relatively long time; see Loewenstein at al. in Cellular Immunology, 77 (1983) 290-297. It has also been assumed and formally proved that lipoproteins from mycoplasma exhibit such an activity; see Herbelin at al. in Infect. Immun., 62 (1994) 4690-4694 and Mühlradt at al. in Biochemistry, 35 (1996) 7781-7786. Lipoproteins from Gram-negative bacteria and analogues of those lipoproteins are likewise immunomodulators and have been described specifically as macrophage activators; see Melchers et al. in J. Exp. Med., 142 (1975) 473-482 and Hoffmann et al.
- Those species of lipoproteins carry an N-terminal S-(2,3-dihydroxy-propyl)-cysteine group (Dhc) having three long-chain fatty acids, of which two are bonded in the form of esters and one is bonded in the form of an amide.
- Dhc N-terminal S-(2,3-dihydroxy-propyl)-cysteine group
- Lipoproteins and synthetic lipopeptide analogues have a half-maximum effective concentration (Max/2) of approximately 10 ⁇ 7 M; see Melchers at al. in J. Exp. Med., 142 (1975) 473-482 and Hoffmann et at in Biol. Chem. Hoppe Seyler, 370 (1989) 575-582.
- Synthetic analogues without the amide fatty acid have a half-maximum effective concentration (Max/2) of approximately 18 ⁇ 8 M; see Metzger at al. in J. Peptide Scie., 3 (1995) 184-190. Furthermore, in Tetrahedron, 45 (1989) 6331-6360, 6352, Baschang described a taurine-modified lipopeptide (sodium sulphonate: CGP-31 362) which, according to Dong et al. in J. Exp. Med., 177 (1993) 1071-1077, still has macrophage-activating action at from 1 to 10 ng/ml or from 1 to 10 ⁇ 10 ⁇ 9 M. Finally, in J. Peptide Scie.
- the two fatty acid radicals may have the formula R—CO—, wherein R is a C 7 -C 25 -alkyl, C 7 -C 25 -alkenyl or C 7 -C 25 -alkynyl radical, unsaturated radicals preferably being present in the cis configuration.
- R is a C 7 -C 25 -alkyl, C 7 -C 25 -alkenyl or C 7 -C 25 -alkynyl radical, unsaturated radicals preferably being present in the cis configuration.
- Examples of C 7 -C 25 -alkyl, -alkenyl and -alkynyl radicals are C 16 and C 18 radicals.
- composition comprising a S-(2,3-dihydroxypropyl)-cysteine peptide according to the invention together with a conventional carrier and/or adjuvant.
- the composition according to the invention can be used for stimulating the synthesis of antibodies, for preventing infections (anti-infective activity), as an immunostimulant against tumours, for activating macrophages, for developing tolerance towards endotoxins or in the case of septic shock, especially in the case of Gram-negative bacteria, or as a vaccine adjuvant (admixture with a vaccine).
- S-(2,3-dihydroxypropyl)-cysteine peptides can be prepared in a fully synthetic manner.
- the person skilled in the art can proceed analogously to the cited prior art.
- the lipopeptide is prepared from Mycoplasma fermentans (for example PG18).
- the isolation of the lipopeptide from mycoplasma is carried out by the following known separation procedure (Mühlradt et al. in Biochemistry, 35 (1996) 7781-7786).
- Detection of the biological activity is effected by measuring nitrite and nitrate as the secondary products of nitrogen monoxide, which is liberated on stimulation of interferon-treated murine peritoneal macrophages.
- the active ingredient is a S-(2,3-dihydroxypropyl)-cysteine peptide which has two long-chain fatty acids (C16:0 and C18:0/C18:1) bonded in the form of esters at the dihydroxypropyl group, and which has the following sequence:
- the most frequent molecular weight is 2164.
- the substance has the property of stimulating macrophages of mice and humans to release cytokines and prostaglandins, with all the consequences of indirect stimulation of T and B lymphocytes; see Mühlradt et al. in Infect. Immun., 59 (1991) 3962-3968 and Feng & Lo in Infect. Immun., 62 (1994) 3916-3921.
- Its half-maximum effective concentration (Max/2) is 20 pg/ml or 10 ⁇ 11 M in the mouse system. That effective concentration is lower by a factor of from 10 2 to 10 3 than the corresponding known concentrations of similar natural or synthetic lipopeptides.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a S-(2,3-dihydroxypropyl)-cysteine peptide which has two long-chain fatty acids bonded in the form of esters at the dihydroxypropyl group, and which has the following sequence:
The invention relates also to a composition comprising the mentioned peptide.
Description
- This application is a continuation of U.S. patent application Ser. No. 10/385,098 filed Mar. 10, 2003 entitled “Dihydroxypropyl-Cysteine Peptide and Agent Containing this Peptide” which is a division of U.S. patent application Ser. No. 09/331,087 filed Jun. 16, 1999, now U.S. Pat. No. 6,573,242 B1 granted Jun. 3, 2003, which is a 371 filing of international patent application PCT/EP97/07090 filed Dec. 17, 1997 which claims priority benefits of German Patent Application DE 1 96 52 586.1 filed Dec. 17, 1996, the disclosures of all are hereby incorporated by reference.
- The macrophage-stimulating activity of mycoplasma has been known for a relatively long time; see Loewenstein at al. in Cellular Immunology, 77 (1983) 290-297. It has also been assumed and formally proved that lipoproteins from mycoplasma exhibit such an activity; see Herbelin at al. in Infect. Immun., 62 (1994) 4690-4694 and Mühlradt at al. in Biochemistry, 35 (1996) 7781-7786. Lipoproteins from Gram-negative bacteria and analogues of those lipoproteins are likewise immunomodulators and have been described specifically as macrophage activators; see Melchers et al. in J. Exp. Med., 142 (1975) 473-482 and Hoffmann et al. in Immunobiol., 177 (1988) 158-170. Those species of lipoproteins carry an N-terminal S-(2,3-dihydroxy-propyl)-cysteine group (Dhc) having three long-chain fatty acids, of which two are bonded in the form of esters and one is bonded in the form of an amide.
- Lipoproteins and synthetic lipopeptide analogues have a half-maximum effective concentration (Max/2) of approximately 10−7 M; see Melchers at al. in J. Exp. Med., 142 (1975) 473-482 and Hoffmann et at in Biol. Chem. Hoppe Seyler, 370 (1989) 575-582.
- Synthetic analogues without the amide fatty acid have a half-maximum effective concentration (Max/2) of approximately 18−8 M; see Metzger at al. in J. Peptide Scie., 3 (1995) 184-190. Furthermore, in Tetrahedron, 45 (1989) 6331-6360, 6352, Baschang described a taurine-modified lipopeptide (sodium sulphonate: CGP-31 362) which, according to Dong et al. in J. Exp. Med., 177 (1993) 1071-1077, still has macrophage-activating action at from 1 to 10 ng/ml or from 1 to 10×10−9 M. Finally, in J. Peptide Scie. 3 (1995) 184-190, Metzger et al. describe a Dhc peptide having the amino acid sequence CFE PPP ATT T (SEQ ID NO: 2), two palmitoyl groups being bonded to the 2,3-dihydroxypropyl group. The half-maximum effective concentration (Max/2) of that known peptide is 16 ng/ml or 10×10−9 M.
- There is, however, still a need for effective lipopeptides.
- According to the invention there is now proposed a S-(2,3-dihydroxypropyl)-cysteine peptide having two fatty acids, which may be identical or different, bonded to the dihydroxypropyl group in the form of esters, the peptide having the following amino acid sequence (I):
-
(SEQ ID NO: 1) DhcGN NDE SNI SEK EK (SEQ ID NO: 1) (I) or (SEQ ID NO: 1) 1 Dhcys Gly Asn Asn Asp Glu Ser Asn Ile Ser Phe Lys 13 Glu Lys
or an amino acid sequence that is identical to the sequence (I) except that the two N-terminal amino acids in positions 2 and, optionally, 3 are missing and/or one or two C-terminal amino acids have been deleted. - According to the invention, the two fatty acid radicals may have the formula R—CO—, wherein R is a C7-C25-alkyl, C7-C25-alkenyl or C7-C25-alkynyl radical, unsaturated radicals preferably being present in the cis configuration. Examples of C7-C25-alkyl, -alkenyl and -alkynyl radicals are C16 and C18 radicals.
- According to the invention there is also provided a composition comprising a S-(2,3-dihydroxypropyl)-cysteine peptide according to the invention together with a conventional carrier and/or adjuvant. The composition according to the invention can be used for stimulating the synthesis of antibodies, for preventing infections (anti-infective activity), as an immunostimulant against tumours, for activating macrophages, for developing tolerance towards endotoxins or in the case of septic shock, especially in the case of Gram-negative bacteria, or as a vaccine adjuvant (admixture with a vaccine).
- According to the invention, S-(2,3-dihydroxypropyl)-cysteine peptides can be prepared in a fully synthetic manner. The person skilled in the art can proceed analogously to the cited prior art. Reference is made also to DE 35 46 150 A1, DE 37 00 173 A1, DE 38 13 821 A1, DE 41 19 856 A1 and DE 43 29 309 A1.
- The invention is explained in greater detail below with reference to an Example.
- The lipopeptide is prepared from Mycoplasma fermentans (for example PG18). The isolation of the lipopeptide from mycoplasma is carried out by the following known separation procedure (Mühlradt et al. in Biochemistry, 35 (1996) 7781-7786).
- (i) Delipidation of the mycoplasma using chloroform/methanol.
- (ii) Extraction of the delipidated mycoplasma using hot 25 mM octyl glucoside.
- (iii) Dialysis of the detergent extract.
- (iv) Concentration of the extract by lyophilisation.
- (v) Reversed-phase chromatography on a C8 column using a water/2-propanol gradient.
- Detection of the biological activity is effected by measuring nitrite and nitrate as the secondary products of nitrogen monoxide, which is liberated on stimulation of interferon-treated murine peritoneal macrophages.
- The active ingredient is a S-(2,3-dihydroxypropyl)-cysteine peptide which has two long-chain fatty acids (C16:0 and C18:0/C18:1) bonded in the form of esters at the dihydroxypropyl group, and which has the following sequence:
-
(SEQ ID NO: 1) Dhc-GNN DES NIS FKE K - The most frequent molecular weight is 2164. In addition, it is possible to find variants which are distinguished by different fatty acids and by a peptide that is shortened by two C-terminal amino acids.
- The substance has the property of stimulating macrophages of mice and humans to release cytokines and prostaglandins, with all the consequences of indirect stimulation of T and B lymphocytes; see Mühlradt et al. in Infect. Immun., 59 (1991) 3962-3968 and Feng & Lo in Infect. Immun., 62 (1994) 3916-3921. Its half-maximum effective concentration (Max/2) is 20 pg/ml or 10−11 M in the mouse system. That effective concentration is lower by a factor of from 102 to 103 than the corresponding known concentrations of similar natural or synthetic lipopeptides.
Claims (10)
1. S-(2,3-Dihydroxypropyl)-cysteine peptide having two fluty acids, which may be identical or different, bonded in the form of esters to the dihdroxypropyl group, the peptide having the following ammo acid sequence (I):
DheGN NDE SNI SFK EK (SEQ ID NO: 1)
or an amino acid sequence that is identical to sequence (I) except that the N-terminal amino acids in positions 2 and, optionally, 3 are missing and/or one or two C-terminal ammo acids have been deleted.
2. S42,3-Dihydroxypropyl)-cysteine peptide according to claim 1 , wherein that the two fatty acid radicals have the formula R—CO—, wherein R is a C7-C25-alkyl, C7-C25-alkenyl or C7-C25-alkynyl group, unsaturated radicals preferably being present in the cis configuration.
3. Composition comprising a S-(2,3-dihydroxypropyl)-cysteine peptide according to claim 1 together with a conventional carrier and/or adjuvant.
4. Composition according to claim 3 for stimulating the synthesis of antibodies.
5. Composition according to claim 3 for preventing infections (anti-infective activity).
6. Composition according to claim 3 for immunostimulation against tumours.
7. Composition according to claim 3 for activating macrophages.
8. Composition according to claim 3 for developing tolerance towards endotoxins (septic shock), especially in the case of Gram-negative bacteria.
9. Composition according to claim 3 as a vaccine adjuvant (admixture with a vaccine).
10. Composition according to claim 3 for short-term protection against infections, especially Crowding disease, in animals, especially livestock, working animals or domestic animals.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/211,561 US20130178412A1 (en) | 1996-12-17 | 2008-09-16 | Dihydroxyproply-cysteine peptide and agent containing this peptide |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE(1)9652586.1 | 1996-12-17 | ||
| DE19652586A DE19652586A1 (en) | 1996-12-17 | 1996-12-17 | Dhc peptide and agent |
| US09/331,087 US6573242B1 (en) | 1996-12-17 | 1997-12-17 | Dihydroxypropyl cysteine peptide and agent containing this peptide |
| PCT/EP1997/007090 WO1998027110A2 (en) | 1996-12-17 | 1997-12-17 | Dihydroxypropyl cysteine peptide and agent containing this peptide |
| US10/385,098 US7435790B2 (en) | 1996-12-17 | 2003-03-10 | Dihydroxypropyl cysteine peptide and agent containing this peptide |
| US12/211,561 US20130178412A1 (en) | 1996-12-17 | 2008-09-16 | Dihydroxyproply-cysteine peptide and agent containing this peptide |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/385,098 Continuation US7435790B2 (en) | 1996-12-17 | 2003-03-10 | Dihydroxypropyl cysteine peptide and agent containing this peptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20130178412A1 true US20130178412A1 (en) | 2013-07-11 |
Family
ID=7815068
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/331,087 Expired - Lifetime US6573242B1 (en) | 1996-12-17 | 1997-12-17 | Dihydroxypropyl cysteine peptide and agent containing this peptide |
| US10/385,098 Expired - Fee Related US7435790B2 (en) | 1996-12-17 | 2003-03-10 | Dihydroxypropyl cysteine peptide and agent containing this peptide |
| US12/211,561 Abandoned US20130178412A1 (en) | 1996-12-17 | 2008-09-16 | Dihydroxyproply-cysteine peptide and agent containing this peptide |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/331,087 Expired - Lifetime US6573242B1 (en) | 1996-12-17 | 1997-12-17 | Dihydroxypropyl cysteine peptide and agent containing this peptide |
| US10/385,098 Expired - Fee Related US7435790B2 (en) | 1996-12-17 | 2003-03-10 | Dihydroxypropyl cysteine peptide and agent containing this peptide |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US6573242B1 (en) |
| EP (1) | EP0946590B1 (en) |
| AT (1) | ATE261989T1 (en) |
| DE (2) | DE19652586A1 (en) |
| DK (1) | DK0946590T3 (en) |
| ES (1) | ES2218714T3 (en) |
| WO (1) | WO1998027110A2 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19652586A1 (en) * | 1996-12-17 | 1998-06-18 | Biotechnolog Forschung Gmbh | Dhc peptide and agent |
| DE19822820A1 (en) * | 1998-05-20 | 1999-11-25 | Biotechnolog Forschung Gmbh | Wound healing composition comprising lipopeptide or lipoprotein that stimulates leukocyte infiltration |
| DE10048840A1 (en) * | 2000-10-02 | 2002-04-11 | Biotechnolog Forschung Gmbh | Use of lipopeptides or lipoproteins to treat lung infections and tumors |
| SI1490106T1 (en) | 2002-04-04 | 2009-02-28 | Helmholtz Infektionsforschung | Use of a lipopeptide or lipoprotein as an adjuvant in therapeutic or prophylactic vaccinations |
| EP1382352A1 (en) * | 2002-07-19 | 2004-01-21 | GBF Gesellschaft für Biotechnologische Forschung mbH | Bisacyloxypropylcystein conjugates and the use thereof |
| DE102009034779A1 (en) | 2009-07-25 | 2011-02-03 | Emc Microcollections Gmbh | Synthetic analogues of bacterial lipopeptides and their application for the therapy and prophylaxis of allergic diseases |
| EP2305283A1 (en) | 2009-09-24 | 2011-04-06 | Helmholtz-Zentrum für Infektionsforschung GmbH | Pharmaceutical compositions for treating dysregulated inflammatory diseases |
| JP6137834B2 (en) | 2010-02-24 | 2017-05-31 | アローヘッド ファーマシューティカルズ インコーポレイテッド | Composition for targeted delivery of siRNA |
| JP2013542928A (en) | 2010-09-30 | 2013-11-28 | フランバックス ソチエタ レスポンサビリタ リミテ | Generation of virosome particles |
| DE102011018499A1 (en) | 2011-04-23 | 2012-10-25 | Emc Microcollections Gmbh | Topical nanoparticle vaccine for the immune stimulation of dendritic cells in the skin |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3950542A (en) * | 1967-02-21 | 1976-04-13 | L'oreal | Cysteamine derivatives for oral treatment of seborrhea |
| US5214062A (en) * | 1992-04-08 | 1993-05-25 | Clintec Nutrition Co. | Method and composition for treating immune disorders, inflammation and chronic infections |
| US5358933A (en) * | 1991-02-11 | 1994-10-25 | Biosynth S.R.L. | Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock |
| WO1998027110A2 (en) * | 1996-12-17 | 1998-06-25 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Dihydroxypropyl cysteine peptide and agent containing this peptide |
| US5788962A (en) * | 1995-01-17 | 1998-08-04 | The Curators Of The University Of Missouri | DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures |
| WO1999059610A2 (en) * | 1998-05-20 | 1999-11-25 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Use of lipopeptides or lipoproteins for wound treatment |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0014815A3 (en) * | 1978-12-20 | 1980-10-29 | Ciba-Geigy Ag | Peptide derivatives, process for their preparation and intermediates, and pharmaceutical compositions containing one of these compounds |
| US5179079A (en) * | 1986-12-16 | 1993-01-12 | Novo Nordisk A/S | Nasal formulation and intranasal administration therewith |
| US5583198A (en) * | 1989-12-22 | 1996-12-10 | Commonwealth Scientific And Industrial Research Organization | Amino acids, peptides or derivatives thereof coupled to fats |
| DE4119856A1 (en) * | 1991-06-17 | 1992-12-24 | Hoechst Ag | N-ACYL-S- (2-HYDROXYALKYL) -CYSTEINS, THE PRODUCTION AND USE THEREOF AS INTERMEDIATE PRODUCTS FOR THE PRODUCTION OF SYNTHETIC IMMUNE ADJUVANTS AND SYNTHETIC VACCINANTS |
| EP0604945A1 (en) * | 1992-12-28 | 1994-07-06 | Takeda Chemical Industries, Ltd. | TAN-1511, its derivatives, production and use thereof |
| JP3735388B2 (en) * | 1994-06-03 | 2006-01-18 | エム バイオ テック株式会社 | Novel glyceroglycophospholipid, its antibody and mycoplasma detection method |
| US5856444A (en) * | 1994-11-30 | 1999-01-05 | Chugai Seiyaku Kabushiki Kaisha | Thrombocytopoiesis stimulating factor |
| US5817461A (en) * | 1996-01-03 | 1998-10-06 | Hamilton Civic Hospitals Research Development Inc. | Methods and compositions for diagnosis of hyperhomocysteinemia |
| US20020155117A1 (en) * | 1996-04-04 | 2002-10-24 | Nicole Suciu-Foca | Method for detecting organ allograft rejection and uses thereof |
| US6506892B1 (en) * | 1997-10-29 | 2003-01-14 | Andrew C. Webb | Polynucleotides encoding a mycoplasma protein involved in cell growth regulation |
| DE10048840A1 (en) * | 2000-10-02 | 2002-04-11 | Biotechnolog Forschung Gmbh | Use of lipopeptides or lipoproteins to treat lung infections and tumors |
| SI1490106T1 (en) * | 2002-04-04 | 2009-02-28 | Helmholtz Infektionsforschung | Use of a lipopeptide or lipoprotein as an adjuvant in therapeutic or prophylactic vaccinations |
| EP1382352A1 (en) * | 2002-07-19 | 2004-01-21 | GBF Gesellschaft für Biotechnologische Forschung mbH | Bisacyloxypropylcystein conjugates and the use thereof |
| EP1484064A1 (en) * | 2003-06-04 | 2004-12-08 | Gesellschaft für Biotechnologische Forschung | Therapeutical composition containing dentritic cells and use thereof |
-
1996
- 1996-12-17 DE DE19652586A patent/DE19652586A1/en not_active Withdrawn
-
1997
- 1997-12-17 ES ES97954818T patent/ES2218714T3/en not_active Expired - Lifetime
- 1997-12-17 WO PCT/EP1997/007090 patent/WO1998027110A2/en active IP Right Grant
- 1997-12-17 DK DK97954818T patent/DK0946590T3/en active
- 1997-12-17 EP EP97954818A patent/EP0946590B1/en not_active Expired - Lifetime
- 1997-12-17 AT AT97954818T patent/ATE261989T1/en active
- 1997-12-17 DE DE59711429T patent/DE59711429D1/en not_active Expired - Lifetime
- 1997-12-17 US US09/331,087 patent/US6573242B1/en not_active Expired - Lifetime
-
2003
- 2003-03-10 US US10/385,098 patent/US7435790B2/en not_active Expired - Fee Related
-
2008
- 2008-09-16 US US12/211,561 patent/US20130178412A1/en not_active Abandoned
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3950542A (en) * | 1967-02-21 | 1976-04-13 | L'oreal | Cysteamine derivatives for oral treatment of seborrhea |
| US5358933A (en) * | 1991-02-11 | 1994-10-25 | Biosynth S.R.L. | Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock |
| US5214062A (en) * | 1992-04-08 | 1993-05-25 | Clintec Nutrition Co. | Method and composition for treating immune disorders, inflammation and chronic infections |
| US5788962A (en) * | 1995-01-17 | 1998-08-04 | The Curators Of The University Of Missouri | DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures |
| WO1998027110A2 (en) * | 1996-12-17 | 1998-06-25 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Dihydroxypropyl cysteine peptide and agent containing this peptide |
| US6573242B1 (en) * | 1996-12-17 | 2003-06-03 | Gesellschaft Fuer Biotechnologische | Dihydroxypropyl cysteine peptide and agent containing this peptide |
| US7435790B2 (en) * | 1996-12-17 | 2008-10-14 | Helmholtz-Zentrum Fuer Infektionsforschung Gmbh | Dihydroxypropyl cysteine peptide and agent containing this peptide |
| WO1999059610A2 (en) * | 1998-05-20 | 1999-11-25 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Use of lipopeptides or lipoproteins for wound treatment |
Non-Patent Citations (13)
| Title |
|---|
| Bessler, WG et al, The Journal of Immunology, Vol. 139(3), September 1985, pages 1900-1905. * |
| Calcutt, M.J. et al, Infection and Immunity, Feb. 1999, Vol. 67(2), pages 760-771, Differential posttranslational processing confers intraspecies variation of a major surface lipoprotein and a macrophage-activating lipopeptide of Mycoplasma fermentans. * |
| Chambaud, I et al, Trends in Microbiology, Vol. 7, NO. 12, Dec. 1999, pages 493-499, Interactions between mycoplasma lipoproteins and the host immune system. * |
| Galanos, C et al, Journal of Endotoxin Research, Vol. 6(6), pages 471-476, MALP-2, a Mycoplasma lipopeptide with classical endotoxic properties: end of an era of LPS monoply?. * |
| Hall, Robert H et al, Biochem. J., vol. 319, pages 919-927, 1996, cDNA and genomic cloning and expression of the P48 monocytic differentiation/activation factor, a Mycoplasma fermentans gene product. * |
| Kostyal, DA et al, Infection and Immunity, Sept. 1994, Vol. 62(9), pages 3793-3800. * |
| Muhlradt, Peter F. et al, J. Exp. Med. vol. 185, No 22, June 2, 1997, pages 1951-1958, Isolation, structure elucidation and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentrations. * |
| Muhlradt, PF e tal, Biochemistry, Vol. 35, pages 7781-7786, 1996. * |
| Muhlradt, PF et al, Infection and Immunity, Vol. 59(11), pages 3969-3974, Nov. 1991. * |
| Muhlradt, PF et al, Infection and Immunity, Vol. 62(9), pages 3801-3807, Sept. 1994. * |
| Quentmeier, H et al, Infection and Immunity, May 1990, Vol. 58(5), pages 1273-1280. * |
| SWISS-PROT accession number P94932, Monocytic differentiation/activation factor, name P48. * |
| Wise, K.S. et al, Infection and Immunity, vol. 61(8), pages 3327-3333, August 1993, A Family of strain-variant lipoproteins of Mycoplasma fermentans. * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20030220265A1 (en) | 2003-11-27 |
| DK0946590T3 (en) | 2004-07-19 |
| ES2218714T3 (en) | 2004-11-16 |
| WO1998027110A3 (en) | 1998-09-11 |
| ATE261989T1 (en) | 2004-04-15 |
| EP0946590A2 (en) | 1999-10-06 |
| US6573242B1 (en) | 2003-06-03 |
| EP0946590B1 (en) | 2004-03-17 |
| US7435790B2 (en) | 2008-10-14 |
| DE19652586A1 (en) | 1998-06-18 |
| DE59711429D1 (en) | 2004-04-22 |
| WO1998027110A2 (en) | 1998-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20130178412A1 (en) | Dihydroxyproply-cysteine peptide and agent containing this peptide | |
| Chedid et al. | Enhancement of certain biological activities of muramyl dipeptide derivatives after conjugation to a multi-poly (DL-alanine)--poly (L-lysine) carrier. | |
| Zhang et al. | Bacterial lipoprotein and lipopolysaccharide act synergistically to induce lethal shock and proinflammatory cytokine production. | |
| EP0750506B1 (en) | Broad spectrum antimicrobial compounds and methods of use | |
| Parant | Biologic properties of a new synthetic adjuvant, muramyl dipeptide (MDP) | |
| Havell et al. | Enhanced production of murine interferon gamma by T cells generated in response to bacterial infection. | |
| Boraschi et al. | In vivo stimulation and restoration of the immune response by the noninflammatory fragment 163-171 of human interleukin 1 beta. | |
| RU2757426C2 (en) | Immunogenic fused protein | |
| US4113858A (en) | Novel compounds, compositions and methods of their use | |
| US4461761A (en) | Oligomers of compounds of the muramyl-peptide type and medicaments containing them | |
| Johnson et al. | Synthetic analogues of the N-terminal lipid part of bacterial lipoprotein are B-lymphocyte mitogens in vitro and in vivo | |
| AU705418B2 (en) | Peptides having immunomodulatory activity | |
| US5075287A (en) | Muramyl peptide derivatives and immunoregulating compositions containing them | |
| US4401659A (en) | Muramyl-peptides fixed to peptide-polymers and pharmaceutical compositions containing them | |
| EP0273727A2 (en) | Glycosylated glycopeptides | |
| IE911101A1 (en) | Composition for macrophage activation | |
| EP0553113A4 (en) | ||
| Saiki et al. | Adjuvant activity of purified peptidoglycan of Listeria monocytogenes in mice and guinea pigs | |
| US4693998A (en) | Novel compounds of the muramyl peptide | |
| Majury et al. | Preliminary investigation of the mechanism of inhibition of bovine lymphocyte proliferation by Pasteurella haemolytica A1 leukotoxin | |
| US4957736A (en) | Composition for vaccines | |
| US7358044B2 (en) | Prophylactic and therapeutic benefits of a new class of immune stimulating peptides | |
| Leclerc et al. | Comparison of immunomodulatory activities in mice and guinea pigs of a synthetic desmuramyl peptidolipid triglymyc | |
| WO1997043308A1 (en) | Lipophile derivatives of muramylpeptides for treatment of retroviral infection and induction of chemokines | |
| Parant | Biologic properties of a new synthetic adjuvant, muramyl dipeptide (MDP) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |